14 Most relevant to the elderly, an analysis in patients age ≥75 showed similar efficacy of the four NOACs in preventing stroke/SEE as compared to warfarin, with an overall highly significant reduction in relative risk (RR) of 0.70 (95% CI 0.61–0.80) favouring NOACs, and risk with no significant heterogeneity between trials ( P -heterogeneity = 0.83) ( Figure 3 A ).
← all excerpts
Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation.
1
—
—